Crossject S.A. (ALCJ.PA)

Crossject S.A. (ALCJ.PA) — VMCI valuation read

The headline on Crossject S.A. (ALCJ.PA) is a 36/100 VMCI score, set against a Healthcare sector median of 50. That 14-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

ALCJ.PA insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** ALCJ.PA trades at 15.0x earnings, 17% below the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -1.5x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on ALCJ.PA.

ALCJ.PA rose 1.3% over the trailing 7 days, with a -4.7% read on a 30-day basis.